ENTITY
Biocytogen Pharmaceuticals (Beijing)

Biocytogen Pharmaceuticals (Beijing) (2315 HK)

30
Analysis
Health CareChina
Biocytogen Pharmaceuticals Beijing Co., Ltd. operates as a biopharmaceutical and revenue generating pre clinical research services company. The Company produces mmunoglobulins, monoclonal antibodies, recombinant humanized antibodies, and others. Biocytogen Pharmaceuticals Beijing provides drug development, therapeutic antibody discovery and development, and other services.
more
Refresh
01 May 2022 08:55

China Healthcare Weekly (Apr.29)-SH Lockdown Impact on Pharma/CXO,China Biotech Categories & Way Out

We analyzed the impact of lockdown to Pharma and CXO, worrying the priority of healthcare may decline.China biotech can be divided into some...

Logo
352 Views
Share
16 Feb 2022 09:14

Pre-IPO Biocytogen Pharmaceuticals - The Novel Development Model Offset the Pipeline's Shortcomings

We analyzed the unique development strategy of Biocytogen, and also pointed out the concerns on its pipeline. However, its business model is hard...

Logo
266 Views
Share
16 Nov 2021 11:40

Biocytogen (百奥赛图) Pre-IPO: Peer Comparison and Prelim Valuation for Animal CRO

We will compare Biocytogen's business with its close animal CRO peers which filed listing applications to list on the A-share market recently, and...

Logo
238 Views
Share
bullishGQG Partners
17 Oct 2021 10:27

ECM Weekly (17th October 2021) - SG Lottery, GQG, Judo Bank, Vulcan Steel, Biocytogen, Kakao Pay

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.

Logo
348 Views
Share
13 Oct 2021 10:33

Biocytogen (百奥赛图) Pre-IPO: From Animal CRO to Biotech

We look at Biocytogen's main business line of animal CRO (gene-edited mice) and also its two core assets YH003 and YH001.

Logo
302 Views
Share
x